Rezultati - Canes, Jordi

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

    Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial od Adamo, Barbara, Bellet, Meritxell, Paré, Laia, Pascual, Tomás, Vidal, Maria, Pérez Fidalgo, José A., Blanch, Salvador, Martinez, Noelia, Murillo, Laura, Gómez-Pardo, Patricia, López-González, Ana, Amillano, Kepa, Canes, Jordi, Galván, Patricia, González-Farré, Blanca, González, Xavier, Villagrasa, Patricia, Ciruelos, Eva, Prat, Aleix

    Izdano 2019
    Polni tekst Polni tekst Polni tekst
    Text
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

    Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial od Pascual, Tomás, Oliveira, Mafalda, Villagrasa, Patricia, Ortega, Vanesa, Paré, Laia, Bermejo, Begoña, Morales, Serafín, Amillano, Kepa, López, Rafael, Galván, Patricia, Canes, Jordi, Salvador, Fernando, Nuciforo, Paolo, Rubio, Isabel T., Llombart-Cussac, Antonio, Di Cosimo, Serena, Baselga, José, Harbeck, Nadia, Prat, Aleix, Cortés, Javier

    Izdano 2021
    Polni tekst Polni tekst Polni tekst
    Text
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

    Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opt... od Gavilá, Joaquín, Oliveira, Mafalda, Pascual, Tomás, Perez-Garcia, Jose, Gonzàlez, Xavier, Canes, Jordi, Paré, Laia, Calvo, Isabel, Ciruelos, Eva, Muñoz, Montserrat, Virizuela, Juan A., Ruiz, Isabel, Andrés, Raquel, Perelló, Antonia, Martínez, Jerónimo, Morales, Serafín, Marín-Aguilera, Mercedes, Martínez, Débora, Quero, Juan C., Llombart-Cussac, Antonio, Prat, Aleix

    Izdano 2019
    Polni tekst Polni tekst Polni tekst
    Text
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study

    First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study od Pernas, Sonia, Villagrasa, Patricia, Vivancos, Ana, Scaltriti, Maurizio, Rodón, Jordi, Burgués, Octavio, Nuciforo, Paolo, Canes, Jordi, Paré, Laia, Dueñas, Marta, Vidal, Maria, Cejalvo, Juan Miguel, Perelló, Antonia, Llommbard-Cussac, Antonio, Dorca, Joan, Montaño, Alvaro, Pascual, Tomás, Oliveira, Mafalda, Ribas, Gloria, Rapado, Inmaculada, Prat, Aleix, Ciruelos, Eva

    Izdano 2021
    Polni tekst Polni tekst Polni tekst
    Text
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: